The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Soupdragon78, thanks for the subsequent post. That clarifies it, much appreciated.
Should stop having garlic with my coffee with my breakfast, the bloody french garlic lol. From Monday no more onions, garlic or olives. there will be smoked salmon, foie gras et caviar instead, courtesy of FDA, CFDA, Roche and more RNSs
Comek, Roche are a global company who sell their products everywhere, hence they have a platform.
Novacyt have designed a product that can be used on one of Roche’s products and has been validated by Roche, I.e they’ve tested it and said all is good.
That doesn’t mean Roche are going to sell it, that means that Novacyt can say in their literature that the test is compatible with the LightCycler.
They have also validated it with two other thermal cycler manufacturers, does that mean a JV with those as well?
Imagine you invent a new tyre for cars, you would want Ford, Toyota etc to validate it works with their car as it makes it more attractive to your market, it doesn’t mean ford will start selling your tyres.
Soupdragon78 thanks, But she staying, to quote, “the Roche PLATFORM global coverage WILL HELP us to REACH THE MAXIMUM NUMBER OF PATIENTS.”
Not trying to be funny or insist, but maybe I’m a little thick:
sentence : subject + verb + object
”Roche platform global coverage” will be doing the action “help us to reach”. ???????
Thanks for the correction B2H.
Also see page two of the NCYT CE marked test handbook for compatable thermal cyclers. This allows the test to be used without always buying new cyclers.
https://www.genesig.com/assets/files/Path_Coronavirus_COVID_19_CE_IVD_IFU_Issue_10.pdf?timestamp=1582360300
Soupdragon,
Please refer to the following RNS's.
We do manufacture our own instruments, and have supplied the to China.
13.05.2019 - Launch of Next-Generation qPCR Instrument
06.12.2019 - Completion of q16 molecular diagnostics order
Comek, she is talking about validation of the test using the Roche LightCycler thermal cycler.
It’s also been validated by Applied Biosystems and Bio-Rad.
It’s not a JV. It about product testing.
Thanks AngryAnt,
I take your point. However, the quote is from nyct R&D manager. She seems to be stating as a fact ie deal done, see capitals. So either a jv, or ncyt will have to pay Roche to pay for the distribution platform . So in either case a deal appears to have been struck, no. This also ties in with the fact the FDA to grant approval nyct has to provide evidence they are able to delivery the test when and where is needed. Just trying to understand to get my head around it, I’m sure others would help clarifying it.
It’s about compatibility with PCR platforms that can provide the reading for the test.
Novacyt have tested the product with Roche Lightcycler 480 II and also Applied Biosystems PCR 7500 and Bio-Rad CFX96.
Novacyt don’t make equipment to run the test so they have to ensure that it can be undertaken on standard thermal cyclers.
Am I reading the below correctly that a jv/licensing practically done, left to be announced?
No ramping please it just give ammunition to derampers. As many have said Ncyt doesn’t need ramping. The remotest village in the planet must have heard of coronavirus and **** is increasingly becoming synonymous with it.
My capitals of course.
Claire Monk
Head of R&D at PrimerDesign Ltd
Thank you so much for your endorsement of our Coronavirus kits. It means a lot TO GET THAT LEVEL OF SUPPORT from one of the diagnostics behemoths. I am so proud of the team for what they achieved and hope that by having validated on the Lightcycler, the Roche platform global coverage will help us to REACH THE MAXIMUM NUMBER OF PATIENTS.
https://www.linkedin.com/posts/crenguta-strimbeanu-dinu-82702a37_primerdesign-launches-coronavirus-qpcr-pathogen-activity-6635804793291980801-7Y1F